Dianthus Therapeutics, Inc. (DNTH)
(Delayed Data from NSDQ)
$21.24 USD
-0.26 (-1.21%)
Updated Aug 5, 2025 04:00 PM ET
After-Market: $21.13 -0.11 (-0.52%) 7:58 PM ET
4-Sell of 5 4
F Value F Growth A Momentum F VGM
Fundamental Charts
About Market Cap
As of the previous market close, Dianthus Therapeutics, Inc. has a market cap of $691.44M, which represents its share price of $21.50 multiplied by its outstanding shares number of 32.16M. As a small-cap company, DNTH's shareholders are generally exposed to more risk than shareholders of mid and large-cap companies.
The company's Market Capitalization is a measurement of company size. It is calculation of the company's share price times the number of outstanding shares. Large market cap companies give stability and are good long-term investments. Small market cap companies can produce faster growth and bigger returns, but their stockholders are exposed to more risk.
DNTH 21.24 -0.26(-1.21%)
Will DNTH be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for DNTH based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for DNTH
Dianthus Therapeutics, Inc. (DNTH) Reports Q1 Loss, Tops Revenue Estimates
Emergent Biosolutions (EBS) Q1 Earnings Top Estimates
DNTH: What are Zacks experts saying now?
Zacks Private Portfolio Services
Dianthus Therapeutics, Inc. (DNTH) Soars 6.1%: Is Further Upside Left in the Stock?
Alnylam (ALNY) Surges 11.8%: Is This an Indication of Further Gains?
Dianthus Therapeutics, Inc. (DNTH) Reports Q4 Loss, Misses Revenue Estimates
Other News for DNTH
Commit To Buy Dianthus Therapeutics At $12.50, Earn 26.6% Annualized Using Options
Dianthus (DNTH) Price Target Raised by Guggenheim Ahead of Key Trial
Dianthus price target raised by $8 at Guggenheim, here's why
Dianthus initiated with bullish view at William Blair, here's why
Dianthus Therapeutics (DNTH) Receives Outperform Rating by William Blair | DNTH Stock News